Piper Jaffray Companies Lowers Bioverativ (BIVV) to Neutral
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Bioverativ from a hold rating to a buy rating and set a $62.00 price target on the stock in a report on Monday, January 8th. Deutsche Bank set a $53.00 target price on Bioverativ and gave the stock a hold rating in a report on Monday, November 20th. Credit Suisse Group restated a neutral rating and set a $65.00 target price on shares of Bioverativ in a report on Thursday, January 18th. Morgan Stanley restated an underweight rating and set a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Finally, Royal Bank of Canada raised their target price on Bioverativ to $68.00 and gave the stock a market perform rating in a report on Thursday, January 18th. Twelve investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Bioverativ currently has an average rating of Hold and an average target price of $62.53.
Bioverativ (NASDAQ:BIVV) traded down $0.63 during trading on Monday, reaching $103.16. The company had a trading volume of 10,083,220 shares, compared to its average volume of 3,192,829. The company has a market capitalization of $11,160.00 and a PE ratio of 25.22. Bioverativ has a fifty-two week low of $40.99 and a fifty-two week high of $104.30.
A number of institutional investors and hedge funds have recently modified their holdings of BIVV. Quotient Investors LLC acquired a new stake in shares of Bioverativ during the third quarter worth about $420,000. Mutual of America Capital Management LLC acquired a new stake in shares of Bioverativ during the third quarter worth about $5,062,000. Meeder Asset Management Inc. acquired a new stake in shares of Bioverativ during the third quarter worth about $877,000. Rockefeller Financial Services Inc. acquired a new stake in shares of Bioverativ during the third quarter worth about $1,480,000. Finally, State Treasurer State of Michigan acquired a new stake in shares of Bioverativ during the third quarter worth about $2,323,000. Hedge funds and other institutional investors own 96.04% of the company’s stock.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.